Loading...
Loading...
GSK plc
GSK plc. Spoken Alpha tracks GLAXF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks GLAXF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 50% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for GLAXF.
curl https://api.spokenalpha.com/v1/companies/GLAXF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.46 | $2.36 | +46.8% | -3.7% | -5.3% |
| Q4 FY2026 | $3.36 | $2.48 | +35.6% | +0.8% | +2.8% |
| Q3 FY2026 | $3.42 | $2.28 | +49.9% | -3.9% | -3.4% |
| Q2 FY2026 | $3.51 | $2.47 | +42.3% | +3.5% | +5.0% |
| Q1 FY2025 | $3.40 | $2.39 | +42.1% | +2.8% | +5.6% |
| Q4 FY2025 | $3.39 | $2.31 | +46.9% | -1.6% | -0.6% |
| Q3 FY2025 | $3.42 | $2.38 | +43.5% | -1.4% | -1.0% |
| Q2 FY2025 | $3.53 | $2.60 | +35.8% | +0.6% | +3.5% |
| Q1 FY2024 | $3.64 | $2.54 | +43.4% | +4.4% | +4.2% |
| Q4 FY2024 | $3.63 | $2.45 | +48.1% | -2.8% | -0.3% |